Inmaculada Fernández, Esperanza Ulloa, Francisco Colina, Manuel Abradelo, Carlos Jiménez, Alberto Gimeno, Juan Carlos Meneu, Carlos Lumbreras, José Antonio Solís‐Herruzo, Enrique Moreno – 29 July 2009 – Antiviral therapy for recurrent hepatitis C in liver transplantation has been associated with the development of chronic rejection. The aim of this study was to assess the incidence, evolution, and risk factors associated with the development of chronic rejection during posttransplant hepatitis C virus antiviral therapy.

Alan Wigg, Mahinda De Silva, Marcus Teo, Anthony Thomas, Shaun Fowler, John Chen – 29 July 2009

29 June 2009

Maxime Audet, Fabrizio Panaro, Tullio Piardi, Philippe Wolf – 26 June 2009

Nicholas A. Shackel, Jade Jamias, Wassim Rahman, Emilia Prakoso, Simone I. Strasser, David J. Koorey, Michael D. Crawford, Deborah J. Verran, James Gallagher, Geoffrey W. McCaughan – 26 June 2009 – The aim of this study was to examine the importance of the serum hepatitis C viral load within the first year post–liver transplant in determining posttransplant survival.

Darrin L. Willingham, Prith Peiris, Juan M. Canabal, Murli Krishna, Winston R. Hewitt, Timothy S. J. Shine, Lisa C. Arasi, Jaime Aranda‐Michel, Christopher B. Hughes, David J. Kramer – 26 June 2009 – Arterial vasodilation is common in end‐stage liver disease, and systemic hypotension often may develop, despite an increase in cardiac output. During the preparation for and the performance of orthotopic liver transplantation, expected and transient hypotension may be caused by induction agents, anesthetic agents, liver mobilization, or venous clamping.

Noboru Harada, Yuji Soejima, Akinobu Taketomi, Tomoharu Yoshizumi, Hideaki Uchiyama, Toru Ikegami, Toshiharu Saibara, Takashi Nishizaki, Yoshihiko Maehara – 26 June 2009 – Familial hypobetalipoproteinemia (FHBL) is one of the causes of nonalcoholic steatohepatitis (NASH) and a codominant disorder. Patients heterozygous for FHBL may be asymptomatic, although they demonstrate low plasma levels of low‐density lipoprotein (LDL) cholesterol and apolipoprotein B.

Ayse L. Mindikoglu, Laurence S. Magder, Arie Regev – 26 June 2009 – Acute liver failure (ALF) is an uncommon but potentially lethal drug‐related adverse effect that often leads to liver transplantation (LT) or death. A retrospective cohort study was performed with the United Network for Organ Sharing Standard Transplant Analysis and Research files. Recipients who underwent LT for drug‐induced acute liver failure (DIALF) from 1987 through 2006 were analyzed. A total of 661 patients transplanted for DIALF were included in the analysis.

Geoffrey C. Nguyen, Nimisha P. Thuluvath, Dorry L. Segev, Paul J. Thuluvath – 26 June 2009 – Partial hepatectomy for hepatocellular carcinoma (HCC) is a high‐risk procedure, especially in the presence of portal hypertension. We assessed whether the volume of hospital liver transplant procedures was associated with lower in‐hospital mortality independently of the volume of partial hepatectomy procedures.

Atsushi Takebe, Harald Schrem, Bastian Ringe, Frank Lehner, Christian Strassburg, Juergen Klempnauer, Thomas Becker – 26 June 2009 – Split liver transplantation (SLT) is clearly beneficial for pediatric recipients. However, the increased risk of biliary complications in adult recipients of SLT in comparison with whole liver transplantation (WLT) remains controversial. The objective of this study was to investigate the incidence and clinical outcome of biliary complications in an SLT group using split extended right grafts (ERGs) after ex situ splitting in comparison with WLT in adults.